says a US cost-effectiveness body. The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and ...

Manufacturer Janssen says Esketamine can lift a patient's mood ... Administration (FDA)'s advisory panel in February, and can cost up to $885 (£673) per treatment. In a statement, Janssen said ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression ...

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a ...